The exact cause of Eosinophilic Granulomatosis with Polyangiitis (EGPA) is not yet fully understood. However, it is believed to be an autoimmune disease, meaning that the body’s immune system mistakenly attacks its own healthy tissues, particularly the small blood vessels, leading to inflammation.

Researchers believe that environmental or allergic triggers may play a role in some individuals. These triggers may cause the immune system to respond abnormally, resulting in inflammation and damage to blood vessels and surrounding tissues.

Eosinophilic Granulomatosis with Polyangiitis (EGPA) can affect individuals of any age, but it is most commonly diagnosed in young and middle-aged adults. The condition affects men and women equally.

EGPA is more likely to develop in people with a history of allergic conditions, such as allergies, allergic rhinitis (hay fever), or asthma. In fact, asthma and other allergic symptoms are commonly associated with the disease.

Lungs

When Eosinophilic Granulomatosis with Polyangiitis (EGPA) affects the lungs, common symptoms include shortness of breath, persistent coughing, and chest pain. In more severe cases, lung involvement can become life-threatening. Rarely, inflammation can cause bleeding within the lungs, which may result in coughing up blood (hemoptysis).

Nerves

EGPA commonly affects the peripheral nerves, particularly those in the lower limbs. Nerve involvement can cause sudden muscle weakness or loss of movement, such as foot drop (difficulty lifting the front of the foot). This type of nerve damage may occur without significant pain.

Skin

Skin involvement may appear as small red or purple spots known as purpura. These spots are caused by bleeding beneath the skin and can resemble small bruises. They commonly occur on the lower extremities, particularly the legs.

Joints

When EGPA affects the joints, symptoms may include joint pain, aching, stiffness, and swelling. These symptoms can vary in severity.

Digestive System (Gastrointestinal Tract)

Although less common, EGPA can affect the digestive system, including the stomach and intestines. Inflammation in these areas may cause abdominal pain and diarrhea. The kidneys may also be affected by the disease.

Heart

Heart involvement is uncommon but can occur in people with EGPA. One possible complication is pericarditis, which is inflammation of the tissue surrounding the heart. In some cases, EGPA can also affect the heart muscle and other cardiac structures.

Two important features that help identify Eosinophilic Granulomatosis with Polyangiitis (EGPA) are a history of asthma and an elevated number of eosinophils, a type of white blood cell, in the bloodstream. However, diagnosing EGPA can sometimes be challenging because symptoms may fluctuate, with periods of worsening followed by improvement.

A rheumatologist, a specialist in inflammatory conditions, autoimmune diseases, and vasculitis, is often best suited to assess and diagnose EGPA.

The diagnostic process typically begins with a detailed medical history and a thorough physical examination. The physician will then order appropriate investigations, which may include blood tests and imaging studies, such as X-rays, to help confirm the diagnosis and determine which organs and tissues may be affected.

Additional tests may be required depending on the individual’s symptoms and suspected organ involvement. This helps physicians assess the extent of the disease and develop an appropriate treatment plan.

Blood Tests

Measuring eosinophil levels: A Complete Blood Count (CBC) is used to measure the different types of blood cells, including eosinophils. People with Eosinophilic Granulomatosis with Polyangiitis (EGPA) often have an elevated number of these white blood cells.

Checking for inflammation: Since EGPA causes inflammation throughout the body, certain blood tests may show elevated inflammatory markers. Common tests include:

• Complete Blood Count (CBC)
• Erythrocyte Sedimentation Rate (ESR)
• C-Reactive Protein (CRP)

These tests help physicians assess the presence and extent of inflammation.

Detecting ANCA antibodies: The Anti-Neutrophil Cytoplasmic Antibody (ANCA) test looks for antibodies directed against proteins found in neutrophils, a type of white blood cell. ANCA is positive in approximately 30–40% of people with EGPA. However, a negative result does not rule out the disease.

Measuring IgE levels: Immunoglobulin E (IgE) is an antibody associated with allergic responses. IgE levels are often elevated in people with EGPA, although this finding is not specific to the disease.

Kidney Function Tests

Blood and urine tests: Kidney involvement can be assessed using blood and urine tests. A creatinine blood test helps evaluate how well the kidneys are functioning, while a urinalysis checks for abnormalities in the urine, such as blood or protein, which may indicate kidney involvement.

Tissue Biopsy

Biopsy of affected skin or lung tissue: A tissue biopsy may be recommended when Eosinophilic Granulomatosis with Polyangiitis (EGPA) is suspected, particularly in people with skin or lung involvement.

During a biopsy, a small sample of tissue is removed from an affected area and sent to a laboratory for examination under a microscope. This allows physicians to look for signs of inflammation, blood vessel damage (vasculitis), and an accumulation of eosinophils.

A biopsy can help support the diagnosis of EGPA and provide additional information about the extent and nature of tissue involvement.

Causes of Antiphospholipid Antibody Syndrome (APS/APLAS)

The exact cause of antiphospholipid antibody syndrome (APS) is not fully understood. The condition develops when the immune system produces antiphospholipid antibodies that mistakenly target proteins associated with phospholipids, which are essential components of cell membranes.

Researchers believe that a combination of genetic predisposition and environmental factors may contribute to the development of APS. Certain infections, medications, and other immune system triggers may be associated with the temporary presence of antiphospholipid antibodies; however, the presence of these antibodies alone does not necessarily mean that a person has APS.

Further research is needed to understand why some individuals develop persistent antiphospholipid antibodies and go on to experience complications such as abnormal blood clotting or pregnancy loss, while others do not.

X-Rays looking for lung involvement: A chest x-ray or a CT-scan of the chest are often used to look for lung involvement.

Test for heart involvement: An echocardiogram (ECG or EKG) is a test that looks for heart involvement

Tests for nerve involvement: Electromyography or Nerve Conduction Studies can be performed to look for nerve or muscle involvement.

Genetics is believed to play an important role in the development of ankylosing spondylitis (AS).

Approximately 90% of people with AS carry a gene known as HLA-B27, which is associated with an increased risk of developing the condition. However, having this gene does not mean that a person will inevitably develop AS, as many people who carry HLA-B27 never develop the disease.

Although HLA-B27 is an important genetic risk factor, other genetic and environmental factors are also thought to contribute to the development of AS.

Treatment of Eosinophilic Granulomatosis with Polyangiitis

Eosinophilic Granulomatosis with Polyangiitis (EGPA) should be treated promptly and effectively to control inflammation and minimize damage to small blood vessels and vital organs. Managing asthma symptoms is also an important part of treatment and typically involves standard asthma medications and therapies.

A rheumatologist is often the primary specialist involved in diagnosing and managing EGPA. Depending on which organs are affected, patients may also require care from other specialists, such as a respirologist (lung specialist), neurologist (nerve specialist), or nephrologist (kidney specialist).

Medications for Eosinophilic Granulomatosis with Polyangiitis

Corticosteroids (Prednisone)

Prednisone is a commonly used medication for treating EGPA. It works by suppressing the immune system and reducing inflammation caused by the disease. Many patients experience significant improvement in their symptoms with corticosteroid treatment.

As the disease becomes controlled, symptoms improve, and inflammatory markers return to normal, the prednisone dose can be gradually reduced (tapered). Some patients may eventually be able to stop taking the medication, while others may require a low maintenance dose to keep the disease under control.

Cyclophosphamide

Cyclophosphamide is an immunosuppressive medication that may be used in more severe cases of EGPA, particularly when vital organs are affected. It is often prescribed alongside corticosteroids, such as prednisone, to bring the disease under control and reduce the risk of further organ damage.

Azathioprine (Imuran) and Methotrexate

Azathioprine and methotrexate are immunosuppressive medications that may be used for long-term disease management and maintenance of remission.

Patients who have received cyclophosphamide to control severe disease may transition to one of these medications to help maintain remission and reduce the likelihood of relapse.

In less severe cases, azathioprine or other appropriate immunosuppressive treatments may be considered as part of the treatment plan, depending on the individual’s disease activity and organ involvement.

Eosinophilic Granulomatosis with Polyangiitis (EGPA), previously known as Churg-Strauss syndrome, is a very rare condition characterized by inflammation of the small blood vessels, a condition known as vasculitis.

In people with EGPA, inflammation can affect the small blood vessels that supply various tissues and organs, including the lungs, sinuses, skin, and nerves. As a result, the disease can affect almost any organ in the body.

EGPA belongs to a group of inflammatory diseases known as vasculitis. The term vasculitis refers to inflammation of the blood vessels, which can interfere with normal blood flow and damage surrounding tissues.

One of the distinguishing features of EGPA is its strong association with asthma. Asthma is present in virtually all people with this condition, and worsening asthma symptoms are often among the earliest signs of the disease.

The term eosinophilic in the disease’s name refers to an increased number of eosinophils, a type of white blood cell involved in the body’s immune response. These cells can accumulate in tissues and contribute to the inflammation associated with EGPA.

There is no specific diet proven to stop AS or reverse spinal changes. A Mediterranean-style pattern—vegetables and fruit, whole grains, legumes, nuts, fish, and unsaturated fats—is a reasonable approach for overall health. Foods such as tomatoes and bell peppers can be included, but they shouldn’t be considered treatments for AS.

Tomatoes and arthritis

Tomatoes can be a nutritious addition to an arthritis-friendly diet, although they do not cure arthritis or directly reverse joint damage.

• Lycopene: Tomatoes are particularly rich in lycopene, an antioxidant that helps protect cells from oxidative stress. Cooked tomatoes and tomato products can provide especially well-absorbed lycopene.

• Vitamin C: Supports collagen formation and normal connective-tissue function.

• Antioxidants: Tomatoes contain vitamin C, carotenoids, and other plant compounds that contribute to overall antioxidant intake.

• Potential anti-inflammatory effects: Laboratory and observational research suggests that compounds in tomatoes may influence inflammatory pathways, but evidence that eating tomatoes significantly reduces arthritis pain or inflammation in people is still limited.

• Heart health: Tomatoes can contribute to a heart-healthy diet, which is particularly relevant for people with rheumatoid arthritis, because RA is associated with increased cardiovascular risk.

Some people with arthritis report that tomatoes or other nightshade vegetables worsen their symptoms. There isn’t strong scientific evidence that tomatoes generally cause arthritis inflammation or should routinely be avoided. If you consistently notice symptoms after eating a particular food, discussing this pattern with a healthcare professional or dietitian can be more useful than eliminating foods unnecessarily.

For osteoarthritis, tomatoes are best viewed as part of an overall nutritious eating pattern. For rheumatoid arthritis, diet can complement medical treatment but shouldn’t replace disease-modifying medication when it is prescribed.

The exact cause of Eosinophilic Granulomatosis with Polyangiitis (EGPA) remains unknown. However, it is believed to be an autoimmune condition in which the body’s immune system mistakenly attacks its own small blood vessels, leading to inflammation and potential damage to affected tissues and organs.

Researchers believe that allergic or environmental triggers may play a role in the development of the disease. These triggers may contribute to an abnormal increase in eosinophils, a type of white blood cell, in the bloodstream. However, the exact mechanisms behind this process are not yet fully understood.

EGPA is more commonly associated with individuals who have a history of allergic conditions, including allergies, allergic rhinitis (hay fever), and asthma. Asthma, in particular, is a common feature of the disease.